The development of Antibody-Drug Conjugate (ADC) technologies has facilitated the enhanced targeting of cancer cells with reduced toxic side effects compared with traditional small molecule cancer drugs.
Symbiosis’ expertise in sterile fill finish supports pharma and biotech companies to advance their ADC (and other) technology platforms with collaborations to progress ADC Drug Products rapidly to the clinic and market.
Download our ADC manufacturing capabilities sheet to find out more about how Symbiosis are well placed to support your ADC manufacturing requirements.
Fill in your details to be added to our mailing list and receive our latest updates.
